21 L858R腦轉(zhuǎn)移的部分患者，奧希替尼雖然延緩了癥狀性的中樞神經(jīng)系統(tǒng)轉(zhuǎn)移發(fā)生戳气，但并未降低中樞神經(jīng)系統(tǒng)轉(zhuǎn)移的累積發(fā)生率链患。達(dá)可替尼延緩了腦轉(zhuǎn)移的發(fā)生率，也降低了腦轉(zhuǎn)移發(fā)生風(fēng)險(xiǎn)瓶您。
2022年初麻捻，來(lái)自國(guó)家癌癥中心/中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院內(nèi)科王燕教授、楊廣建博士少見(jiàn)突變研究團(tuán)隊(duì)對(duì)HER2突變NSCLC患者一線化療的最佳聯(lián)合策略做了深入研究與對(duì)比呀袱，相關(guān)最新POLISH研究發(fā)表于國(guó)際權(quán)威雜志《Therapeutic Advances in Medical Oncology》 （IF：8.168）贸毕，研究詳細(xì)分類(lèi)了中國(guó)293例NSCLC患者HER2突變分子亞型及其共存突變情況，基于210例HER2擴(kuò)增/突變晚期NSCLC患者的真實(shí)世界療效數(shù)據(jù)夜赵，對(duì)比了一線化療+免疫對(duì)比化療+抗血管及單純化療的療效明棍，從機(jī)制上解釋了此類(lèi)患者一線免疫治療效果不佳的可能原因，為數(shù)年來(lái)中國(guó)肺癌HER2免疫治療療效臨床之爭(zhēng)給出了科學(xué)的回復(fù)寇僧。
Okayama Lung Cancer Study Group Trial 1404
Clin Cancer Res.2022 Feb 1;28(3):461-467.
陸舜摊腋，前瞻性、多中心嘁傀、單臂試驗(yàn) （ChiCTR1800020262） 評(píng)估泛HER抑制劑吡咯替尼在HER2擴(kuò)增的非小細(xì)胞肺癌（NSCLC）患者中的療效和安全性兴蒸。27名HER2擴(kuò)增；The 6-month PFS rate was 51.9% [95% confidence interval (CI), 34.0-69.3]. The median PFS (mPFS) was 6.3 months (95% CI, 3.0-9.6 months), and median OS was 12.5 months (95% CI, 8.2-16.8 months). Pyrotinib elicited a confirmed ORR of 22.2% (95% CI, 10.6%-40.8%). 腦轉(zhuǎn)移患者的ORR為40%细办。
BMC Med. 2022 Feb 1;20(1):42.
多中心类咧、單臂、II 期試驗(yàn)中蟹腾，攜帶 HER2 突變的 IIIB-IV NSCLC 患者ChiCTR1800020262
Seventy-eight patients were enrolled for efficacy and safety analysis. The 6-month PFS rate was 49.5% (95% confidence interval [CI], 39.2-60.8). Pyrotinib produced an ORR of 19.2% (95% CI, 11.2-30.0), with median PFS of 5.6 months (95% CI, 2.8-8.4), and median OS of 10.5 months (95% CI, 8.7-12.3). The median duration of response was 9.9 months (95% CI, 6.2-13.6). Patients with exon 20 and non-exon 20 HER2 mutations had ORRs of 17.7% and 25.0%。
一個(gè)研究?jī)善恼隆?/p>
